The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease

Description

The objective of this prospective, multicenter, randomized, controlled clinical trial is to demonstrate the superiority of the VBX Device for primary patency when compared to bare metal stenting in complex iliac occlusive disease.

Conditions

Aortoiliac Occlusive Disease, Peripheral Arterial Disease

Study Overview

Study Details

Study overview

The objective of this prospective, multicenter, randomized, controlled clinical trial is to demonstrate the superiority of the VBX Device for primary patency when compared to bare metal stenting in complex iliac occlusive disease.

The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease

The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease

Condition
Aortoiliac Occlusive Disease
Intervention / Treatment

-

Contacts and Locations

Denver

North Suburban Medical Center, Denver, Colorado, United States, 80229

Lakeland

Radiology and Imaging Specialists of Lakeland, Lakeland, Florida, United States, 33801

Philadelphia

University of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104

Dallas

The University of Texas Southwestern Medical Center, Dallas, Texas, United States, 75390

Lubbock

Texas Tech University Health Science Center, Lubbock, Texas, United States, 79430

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age ≥ 18 years at time of informed consent signature
  • * Informed Consent Form (ICF) is signed by the subject
  • * Subject can comply with protocol requirements, including follow-up
  • * Patient has symptomatic claudication, rest pain, or minor tissue loss (Rutherford Category 2-5)
  • * Patient has de novo or restenotic lesion(s) found in the common and/or external iliac artery(ies)
  • * Patient has: Unilateral or bilateral single or multiple lesions (\>50% stenosis or chronic total occlusion) each between 4 and 11 cm in length
  • * Patient has a target vessel diameter visually estimated to be approximately between 5 mm and 13 mm
  • * Patient has a sufficient (\<50% stenotic) common femoral artery and at least one sufficient (\<50% stenotic) femoral artery (deep or superficial).
  • * Patient has at least one sufficient (\<50% stenotic) infrapopliteal run-off vessel.
  • * Life expectancy \<1 year
  • * Patient is pregnant at time of informed consent.
  • * Patient has a known allergy to stent or stent graft components (including nitinol, stainless steel, or heparin).
  • * Patient has severe chronic renal insufficiency (serum creatinine level \> 2.5mg/dL) and not undergoing hemodialysis.
  • * Patient has evidence of a systemic infection.
  • * Patient has a known intolerance to antithrombotic medications that prevent compliance with study or control device Instructions for Use.
  • * Patient has had vascular catheterization of the lower extremities within 30 days of randomization (excluding diagnostic angiograms for the study procedure).
  • * Patient has previous stenting in the iliac arteries.
  • * Patient has previous surgical bypass in the target limb.
  • * Patient is currently participating in another investigative clinical study unless received written approval by the sponsor.
  • * Patient has a lesion requiring drug-coated balloon angioplasty, atherectomy, lithotripsy, or any ablative device to facilitate stent delivery.
  • * Patient has an abdominal aortic artery lesion or aneurysm.
  • * Patient has a lesion that requires stent placement within 2 cm of the inguinal ligament.
  • * Patient has isolated common iliac artery stenosis that can be treated with a single device (i.e., common iliac artery stenosis that does not require kissing stents or extend into the external iliac artery).
  • * Patient has outflow disease that requires concomitant interventions (i.e. common femoral endarterectomy or femoral / tibial revascularization).

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

W.L.Gore & Associates,

Study Record Dates

2031-04-30